The inhibition of the Vascular Endothelial Growth Factor (VEGF) and its pathway with anti-angiogenic drugs (e.g., Bevacizumab, Sunitinib), promotes vascular normalization and enhances the effects of RT in situ models of glioblastoma, head and neck cancer, lung cancer, melanoma, and colon cancer [77]. This evidence concerns the gene VEGFA and melanoma.